Rehman Shafi, Ullah Hameed, Nagarajan Jai Sivanandan, Sukaina Mahnoor, Ghafoor Bushra, Shaik Masthan Shameera, Shahrukh Shazmah, Min Allah Hassan, Qureshi Muhammad Hamza
Internal Medicine, Lady Reading Hospital, Peshawar, PAK.
Internal Medicine, Hayatabad Medical Complex, Peshawar, Peshawar, PAK.
Cureus. 2022 Jul 27;14(7):e27338. doi: 10.7759/cureus.27338. eCollection 2022 Jul.
Bevacizumab is a monoclonal anti-vascular endothelial growth factor (VEGF) antibody that binds to and makes all of the VEGF isoforms inactive, and thus prevents angiogenesis, development, and the spread of the tumor. The most reported side effects after administering bevacizumab include bleeding, high blood pressure, heart failure, proteinuria, thrombosis, and gastrointestinal perforation. Pneumothorax has rarely been reported as a complication of bevacizumab, but with an unclear mechanism. This article aims to explore the occurrence of pneumothorax as a side effect after using bevacizumab through a systematic review of current case reports published on the topic. A literature search was conducted using PubMed, Google Scholar, ScienceDirect, and Directory of Open Access through the utilization of appropriate keywords, and case reports were selected based on predefined inclusion and exclusion criteria. Our results encompass five case reports that were further evaluated for demographic, clinical, and treatment parameters. This systematic review concludes that pneumothorax can occur after bevacizumab-containing chemotherapy although this side effect is relatively rare. Awareness regarding this possible side effect can assist clinicians during their practice in considering pneumothorax as a possible differential diagnosis when encountering patients presenting with pulmonary symptoms after starting bevacizumab-containing chemotherapy; hence, timely diagnosis and treatment can save a life.
贝伐单抗是一种单克隆抗血管内皮生长因子（VEGF）抗体，它能与所有VEGF异构体结合并使其失活，从而防止肿瘤血管生成、发展和扩散。使用贝伐单抗后最常报告的副作用包括出血、高血压、心力衰竭、蛋白尿、血栓形成和胃肠道穿孔。气胸作为贝伐单抗的一种并发症很少被报道，但其机制尚不清楚。本文旨在通过系统回顾目前发表的关于该主题的病例报告，探讨使用贝伐单抗后气胸作为副作用的发生情况。通过使用适当的关键词，在PubMed、谷歌学术、ScienceDirect和开放获取期刊目录中进行文献检索，并根据预先定义的纳入和排除标准选择病例报告。我们的结果涵盖了五例病例报告，并对其人口统计学、临床和治疗参数进行了进一步评估。本系统评价得出结论，含贝伐单抗化疗后可能会发生气胸，尽管这种副作用相对罕见。认识到这种可能的副作用有助于临床医生在实践中，在遇到开始含贝伐单抗化疗后出现肺部症状的患者时，将气胸作为一种可能的鉴别诊断加以考虑；因此，及时诊断和治疗可以挽救生命。
